---

---

publishing date : 2021 - 10 - 04    tags : Therapy   

save search

---

Selecta Biosciences Announces Strategic Licensing Agreement with Takeda to Develop Next-Generation Gene Therapies for Patients with Lysosomal Storage Disorders
Published: 2021-10-04 (Crawled : 20:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M |

Health Technology

| -19.6% | O: -0.28% H: 0.49% C: -1.16%
SELB 4 | $0.8812 -8.0% 2.12% 0 |

Health Technology

| -78.69% | O: 0.24% H: 4.53% C: 0.95%
gene therapies gene therapy license therapy

---

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Anniversary Annual Meeting
Published: 2021-10-04 (Crawled : 14:00) - biospace.com/
CUE | $1.57 -0.63% -0.64% 170K |

Health Technology

| -89.77% | O: -1.16% H: 0.42% C: -9.97%
presentation immunotherapy biopharma therapy cancer

---

Candel Therapeutics Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Published: 2021-10-04 (Crawled : 14:00) - biospace.com/
CADL | $5.17 -5.31% -5.61% 520K |

| -48.0% | O: -0.48% H: 2.4% C: -5.36%
immunotherapy therapy cancer

---

Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Published: 2021-10-04 (Crawled : 13:15) - globenewswire.com
TPTX | $76.01 -0.03% |

Health Technology

| 12.86% | O: -0.53% H: 2.39% C: -0.01%
treatment solid tumors positive therapy breakthrough therapy granted grant designation

---

UPDATE: Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
Published: 2021-10-04 (Crawled : 13:15) - globenewswire.com
SIOX | $0.478 -20.5% 40K |

Health Technology

| -78.14% | O: 5.58% H: 6.02% C: 0.88%
europe gene therapies therapy gene therapy

---

Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Published: 2021-10-04 (Crawled : 13:15) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K |

Health Technology

| -87.32% | O: -4.58% H: 2.65% C: 0.49%
TPTX | $76.01 -0.03% |

Health Technology

| 12.86% | O: -0.53% H: 2.39% C: -0.01%
treatment solid tumors positive therapy breakthrough therapy granted designation

---

National Cancer Institute Selects ImmunityBio’s N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy
Published: 2021-10-04 (Crawled : 13:00) - biospace.com/
IBRX | $5.265 7.23% 6.74% 4.6M |

Manufacturing

| -50.4% | O: 1.31% H: 2.69% C: -1.89%
therapy cancer trial keytruda

---

NeuroStar® Advanced Therapy Recognizes National Depression Education and Awareness Month With New Campaign Launch
Published: 2021-10-04 (Crawled : 13:00) - globenewswire.com
STIM | $3.8 -0.78% -0.79% 49K |

Health Technology

| -41.97% | O: -1.06% H: 0.0% C: -3.37%
education therapy depression

---

FDA Grants Orphan Drug Designation (ODD) to AlloVir’s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis
Published: 2021-10-04 (Crawled : 12:00) - biospace.com/
ALVR | $0.7505 1.13% 1.12% 340K |

Health Technology

| -97.03% | O: 6.01% H: 0.0% C: -13.5%
treatment fda orphan drug therapy drug t-cell tollovir designation

---

Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
Published: 2021-10-04 (Crawled : 12:00) - globenewswire.com
SIOX | $0.478 -20.5% 40K |

Health Technology

| -78.14% | O: 5.58% H: 6.02% C: 0.88%
europe gene therapies therapy gene therapy

---

Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Published: 2021-10-04 (Crawled : 12:00) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K |

Health Technology

| -87.32% | O: -4.58% H: 2.65% C: 0.49%
NVCR | $12.09 0.33% 0.33% 850K |

Health Technology

| -89.74% | O: -1.34% H: 0.07% C: -5.6%
treatment phase 2 china therapy cancer trial enroll

---

Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Published: 2021-10-04 (Crawled : 12:00) - biospace.com/
ZLAB | $14.08 -0.99% -0.99% 470K |

Health Technology

| -87.32% | O: -4.58% H: 2.65% C: 0.49%
NVCR | $12.09 0.33% 0.33% 850K |

Health Technology

| -89.74% | O: -1.34% H: 0.07% C: -5.6%
treatment phase 2 china therapy cancer trial enroll

---

SQZ Biotechnologies to Present New Data at the Society for Immunotherapy of Cancer Annual Meeting
Published: 2021-10-04 (Crawled : 11:00) - biospace.com/
SQZ | $0.435 0.0% 30M |

Health Technology

| -97.04% | O: 0.82% H: 0.94% C: -10.32%
immunotherapy therapy cancer biotech iot

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---